Qiagen N.V.

Report azionario NYSE:QGEN

Capitalizzazione di mercato: US$7.2b

Qiagen Crescita futura

Criteri Future verificati 1/6

Qiagen prevede che gli utili e i ricavi cresceranno rispettivamente di 12.4% e 6.1% all'anno. Si prevede che l'EPS crescerà di 11.9% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 13.4% in 3 anni.

Informazioni chiave

12.4%

Tasso di crescita degli utili

11.91%

Tasso di crescita dell'EPS

Life Sciences crescita degli utili17.6%
Tasso di crescita dei ricavi6.1%
Rendimento futuro del capitale proprio13.41%
Copertura analitica

Good

Ultimo aggiornamento18 May 2026

Aggiornamenti recenti sulla crescita futura

Articolo di analisi • Nov 08

Earnings Beat: Qiagen N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Shareholders might have noticed that Qiagen N.V. ( NYSE:QGEN ) filed its quarterly result this time last week. The...
Articolo di analisi • Aug 08

Qiagen N.V. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

NYSE:QGEN 1 Year Share Price vs Fair Value Explore Qiagen's Fair Values from the Community and select yours The...

Recent updates

Nuova narrazione • May 15

Latent TB Testing Expansion And Automation Will Support Stronger Long Term Prospects

Catalysts About Qiagen Qiagen provides molecular diagnostics, sample preparation and bioinformatics tools used in clinical testing and research. What are the underlying business or industry changes driving this perspective?
Nuova narrazione • Apr 30

Latent Tuberculosis And Research Pressures Will Constrain Progress Yet Long-Term Prospects Remain Intact

Catalysts About Qiagen Qiagen provides sample preparation, diagnostic testing and bioinformatics tools for molecular and clinical laboratories. What are the underlying business or industry changes driving this perspective?
Aggiornamento della narrazione • Apr 29

QGEN: Expect Balance Sheet Strength To Support Oncology And Diagnostic Platform Expansion

Qiagen's analyst price target has been adjusted modestly lower to $53.53 from $55.46 as analysts factor in a slightly higher discount rate, a marginally different profit margin outlook, and recent target cuts and rating changes across major banks, alongside some upward revisions earlier in the period. Analyst Commentary Recent research shows a mix of optimism and caution around Qiagen, with several firms adjusting price targets in both directions and a few making rating changes.
Aggiornamento della narrazione • Apr 10

QGEN: I Expect Balance Sheet Strength To Drive Future Shareholder Returns

Qiagen's analyst price target is updated to $55.46. The modest change reflects mixed but generally constructive research commentary that cites an undemanding valuation, a robust balance sheet, and steady recent shareholder returns as key supports.
Aggiornamento della narrazione • Mar 27

QGEN: Possible Sale Prospects Are Expected To Drive Future Returns

The analyst price target for Qiagen has been nudged higher to $55.46 from $55.23, as analysts cite an undemanding valuation, a robust balance sheet, and a track record of average annual shareholder returns of 13% as key supports for the updated view. Analyst Commentary Recent research on Qiagen presents a mix of optimism and caution, with several firms adjusting ratings and price targets while focusing on valuation, balance sheet strength, and execution risk.
Aggiornamento della narrazione • Mar 12

QGEN: Possible Sale And Margin Upside Are Expected To Drive Future Returns

The Analyst Price Target on Qiagen has increased by $2, with analysts citing improved profit margin assumptions and a slightly lower future P/E multiple, while they refine discount rate and revenue growth inputs. Analyst Commentary Bullish and bearish analysts are split on Qiagen, with several firms lifting price targets while others trim estimates or ratings.
Aggiornamento della narrazione • Feb 25

QGEN: Possible Sale And Fresh Takeover Interest Will Drive Future Upside

Analysts have raised their blended price target for Qiagen by about $0.63 to $55.23. This reflects updated views on slightly different revenue growth, profit margin and future P/E assumptions after a mix of recent target increases and reductions across the Street.
Aggiornamento della narrazione • Feb 11

QGEN: Fairly Valued Outlook Will Hinge On Possible Sale And Execution Risks

Qiagen's analyst price target has edged up by about $1 to roughly $55, as analysts factor in slightly higher fair value and profit margin assumptions, along with a modest adjustment to growth expectations and P/E multiples. Analyst Commentary Recent Street research on Qiagen has been active, with several firms adjusting price targets in both directions and a few issuing downgrades.
Aggiornamento della narrazione • Jan 28

QGEN: Fairly Valued Outlook Will Depend On Possible Sale And Leadership Transition

Analysts have slightly raised their Qiagen price target to about $53.32 from $53.23, reflecting small tweaks to revenue growth, discount rate, profit margin, and future P/E assumptions following recent downgrades in Street research. Analyst Commentary Bullish Takeaways Bullish analysts see the updated price target of about US$53.32 as still supported by long term earnings potential, even after recent revisions to revenue growth and profit margin assumptions.
Seeking Alpha • Jan 27

Qiagen: Takeover Optionality With A High-Quality Consumables Platform

Summary QGEN is a consumable molecular diagnostics and life-science tools platform. They offer QuantiFERON, QIAstat-Dx, QIAcuity dPCR, and QDI bioinformatics. Recently, there’s renewed takeover speculation after reports that show they’re weighing strategic options. QGEN’s potential fits include Danaher or Agilent, with Thermo Fisher less likely after the 2020 deal talks failed. QGEN’s portfolio with Parse Biosciences adds single-cell sequencing scale, while 2026 automation launches would further deepen its differentiated workflow. I think QGEN now makes much more sense given the renewed M&A interest. But if deal talks fail or rumors cool, shares could de-rate, so my “Buy” rating is explicitly speculative. Read the full article on Seeking Alpha
Aggiornamento della narrazione • Jan 08

QGEN: Fairly Valued Outlook Will Rely On Leadership Transition And Acquisitions

Narrative Update on Qiagen Analysts have lifted their Qiagen fair value estimate from approximately €50.43 to about €53.23, citing updated assumptions around revenue growth, profit margins and the P/E multiple applied to future earnings. What's in the News Qiagen plans a stock split or significant stock dividend with a 1 to 1.05263 ratio effective January 8, 2026, which adjusts the number of shares while keeping overall value aligned with the split terms (Key Developments).
Articolo di analisi • Jan 07

An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 21% Undervalued

Key Insights The projected fair value for Qiagen is US$59.66 based on 2 Stage Free Cash Flow to Equity Qiagen is...
Aggiornamento della narrazione • Dec 14

QGEN: Stable End Markets Will Support Gradual Sentiment Recovery Ahead

Analysts have trimmed their price target on Qiagen slightly, with a modest fair value reduction of about $0.36 per share. They cite still stable end markets, expectations for gradual improvement ahead, and a view that investment sentiment and valuations have largely bottomed.
Aggiornamento della narrazione • Nov 29

QGEN: Gradual Improvement Ahead As End Markets Remain Stable And Sentiment Bottoms

Analysts have modestly lowered their price target for Qiagen from $55 to $53 per share, citing stable end markets and expectations of gradual improvement ahead. Analyst Commentary Analysts have provided a balanced view of Qiagen's current outlook, highlighting both opportunities and ongoing challenges as the company navigates a gradually improving market environment.
Aggiornamento della narrazione • Nov 15

QGEN: Improving Sentiment And Stable Markets Will Set Stage For Future Upside

Analysts have slightly lowered their price target for Qiagen, reducing it by approximately $0.86 to reflect stable end markets. They also acknowledge that improvement is expected as investment sentiment stabilizes.
Articolo di analisi • Nov 08

Earnings Beat: Qiagen N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Shareholders might have noticed that Qiagen N.V. ( NYSE:QGEN ) filed its quarterly result this time last week. The...
Aggiornamento della narrazione • Oct 31

QGEN: Future Results Will Depend On Automation And Gradual Sentiment Recovery

Analysts have slightly lowered their price target for Qiagen from $55 to $53, citing stable end markets and anticipated gradual improvements in investment sentiment. Analyst Commentary Recent analyst updates highlight a nuanced outlook for Qiagen, with attention drawn to both its strengths and areas of potential risk in the near term.
Aggiornamento della narrazione • Oct 17

Syndromic Diagnostics And Automation Will Shape Future Healthcare

Analysts have slightly lowered their price target for Qiagen, reflecting a small decrease from $51.79 to $51.64 per share. They cite ongoing stability in end markets and expectations for gradual valuation improvement.
Aggiornamento della narrazione • Oct 03

Syndromic Diagnostics And Automation Will Shape Future Healthcare

Analysts have slightly reduced their fair value and price targets for Qiagen, with the consensus moving from approximately $52.39 to $51.79. This change is attributed to stabilizing end markets and expectations of gradual improvement in industry conditions.
Aggiornamento della narrazione • Sep 04

Syndromic Diagnostics And Automation Will Shape Future Healthcare

Analysts remain cautiously optimistic on Qiagen, citing modest macroeconomic improvements and solid company execution despite persistent sector headwinds, resulting in an unchanged consensus price target of $52.39. Analyst Commentary Bullish analysts cite modest improvements in macroeconomic conditions, including easing tariff concerns, as supportive of Qiagen's shares.
Articolo di analisi • Sep 02

Qiagen's (NYSE:QGEN) Strong Earnings Are Of Good Quality

Qiagen N.V.'s ( NYSE:QGEN ) earnings announcement last week was disappointing for investors, despite the decent profit...
Articolo di analisi • Aug 08

Qiagen N.V. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

NYSE:QGEN 1 Year Share Price vs Fair Value Explore Qiagen's Fair Values from the Community and select yours The...
Articolo di analisi • Aug 05

Qiagen N.V.'s (NYSE:QGEN) Share Price Could Signal Some Risk

NYSE:QGEN 1 Year Share Price vs Fair Value Explore Qiagen's Fair Values from the Community and select yours When close...
Seeking Alpha • Feb 25

Qiagen N.V.: Some Clarity Needed Before Buying The Dip

Summary Qiagen N.V., a Netherlands-based medical diagnostics provider, faces market pressure due to some recent NIH funding concerns, despite strong financials and a diverse product portfolio. The company's free cash flow improved markedly in FY 2024, and the company announced a $300 million stock buyback program last month. An analysis around Qiagen N.V. follows in the paragraphs below. Read the full article on Seeking Alpha

Previsioni di crescita degli utili e dei ricavi

NYSE:QGEN - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/20282,40657255778312
12/31/20272,27246752974316
12/31/20262,15540649570516
3/31/20262,099402404615N/A
12/31/20252,090425447654N/A
9/30/20252,071405473658N/A
6/30/20252,040373496675N/A
3/31/20252,00394503680N/A
12/31/20241,97884502674N/A
9/30/20241,96693460633N/A
6/30/20241,94073405576N/A
3/31/20241,939337358521N/A
12/31/20231,965341297459N/A
9/30/20231,954332275432N/A
6/30/20231,978337376519N/A
3/31/20231,999353430580N/A
12/31/20222,142423566715N/A
9/30/20222,226488660826N/A
6/30/20222,261539580770N/A
3/31/20222,313563556755N/A
12/31/20212,252513432639N/A
9/30/20212,240311516745N/A
6/30/20212,190480337592N/A
3/31/20212,065449239571N/A
12/31/20201,870359154458N/A
9/30/20201,71319110298N/A
6/30/20201,61214108333N/A
3/31/20201,550-31152302N/A
12/31/20191,526-41N/A331N/A
9/30/20191,516-25N/A332N/A
6/30/20191,511196N/A342N/A
3/31/20191,507188N/A356N/A
12/31/20181,502190N/A359N/A
9/30/20181,49690N/A325N/A
6/30/20181,48278N/A324N/A
3/31/20181,45355N/A275N/A
12/31/20171,41840N/A287N/A
9/30/20171,38789N/A311N/A
6/30/20171,36275N/A323N/A
3/31/20171,34782N/A353N/A
12/31/20161,33880N/A342N/A
9/30/20161,320123N/A328N/A
6/30/20161,296123N/A331N/A
3/31/20161,281126N/A303N/A
12/31/20151,281130N/A317N/A
9/30/20151,293104N/A310N/A
6/30/20151,315105N/A303N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di QGEN ( 12.4% all'anno) è superiore al tasso di risparmio ( 3.5% ).

Guadagni vs Mercato: Si prevede che gli utili di QGEN ( 12.4% all'anno) cresceranno più lentamente rispetto al mercato US ( 16.8% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di QGEN cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di QGEN ( 6.1% all'anno) crescerà più lentamente rispetto al mercato US ( 11.7% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di QGEN ( 6.1% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di QGEN sarà basso tra 3 anni ( 13.4 %).

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/22 21:15
Prezzo dell'azione a fine giornata2026/05/22 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Qiagen N.V. è coperta da 42 analisti. 16 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Catherine Ramsey SchulteBaird
Luke SergottBarclays
Charles ButlerBarclays